Skip to main content

Autoinflammatory

Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it?https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3
Dr. John Cush @RheumNow( View Tweet )
May 12, 2022
RheumNow Podcast square

What is JAKne? (5.6.2022)

May 06, 2022

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.




  1. Gout affects >10 million (4%) in USA, but now w/ more ethnicity, with highest risk in Native Hawaiians (HR 2.21), followed by Black (1.34) and Japanese (1.14);

Read Article
DMARDs,biologics,RA

Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis

May 04, 2022

Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs. 

Read Article
Retrospective study of 71 adult-onset Still’s disease pts Rx 1st w/ High-dose glucocorticoids shows 41% failed to respond (poor outcome) by week4 w/ WBC as best predictor. If WBC < 13K 60% responded; if ≥13K only 23.5% https://t.co/tMNDgoqP14 https://t.co/xJrIEUU6iK
Dr. John Cush @RheumNow( View Tweet )
May 04, 2022
Biologics for JIA? Not So Fast, Say Insurers It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.https://t.co/w4A5sgv3fU https://t.co/coVh3zui2z
Dr. John Cush @RheumNow( View Tweet )
May 01, 2022
COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients Putman et al has reported vaccine survey results from the C19-GRA in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).https://t.co/sqsOHGThzV https://t.co/zeZrlDeQ9Z
Dr. John Cush @RheumNow( View Tweet )
Apr 25, 2022
Italian retrospective of Canakinumab in 80 kids w/ Systemic JIA - 12 moved from anakinra to CAN w/ iinactive dz/CID. 58 pts w/ active SoJIA started CAN - CID in 57% at 6mos, 64% 12 mos; MAS 3/100PY; Nonresp assoc w/ MAS, #Jts, Dz duration https://t.co/2YmkukU7Z2

Dr. John Cush @RheumNow( View Tweet )

Apr 19, 2022
52% of pediatric rheumatology patients do not make initial appointments or follow ups with adult rheumatology after 2 years of transfer of care! Dr. @hausmannMD #RNL2022 @RheumNow https://t.co/3lVxH1yqud
Dr. Rachel Tate @uptoTate( View Tweet )
Mar 20, 2022
RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

Mar 11, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Single center study of individualized anakinra use in 47 autoinflammatory pts (32kids; 43% MAS; 40% systemic JIA). Off-label use in 38%, higher doses in 21 kids (5-29mg/kg); & 5 given IV anakinra; such doses were well tolerated without major AE. https://t.co/wQgw3YAPKX https://t.co/zL3HfdX4Ns
Dr. John Cush @RheumNow( View Tweet )
Mar 09, 2022
New Download Available! Autoimmune Disease in the USAhttps://t.co/KvsgBUY7mL https://t.co/PSTF7ma6G6
Dr. John Cush @RheumNow( View Tweet )
Mar 07, 2022
COVID,hospital,ER,infusion

Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients

Mar 04, 2022

JAMA has published a meta-analysis of 15 studies of hospitalized patients with COVID-19 treated with tocilizumab and corticosteroids, showing that a clinically meaningful mortality benefit from tocilizumab (and steroids) was best seen in those not requiring invasive mechanical ventilation (

Read Article
Korean study of 53 424 kids with Kawasaki disease (KD) showed that outbreaks of rhinovirus, respiratory syncytial virus and varicella were significantly correlated with KD at 1 to 3 months before KD outbreaks https://t.co/U8FXao1TWn

Dr. John Cush @RheumNow( View Tweet )

Feb 23, 2022
ICYMI: Dr Artie Kavanaugh presents comparison of targeted therapies in different inflammatory disorders. #RWCS2022 @RWCSmtg https://t.co/P4SzIrWzYJ https://t.co/wnf3vnG4xc
Dr. John Cush @RheumNow( View Tweet )
Feb 20, 2022
When to suspect an interferonopathy (when suspected you should offer an autoinflammatory panel from https://t.co/F9bat3YS1d) #RWCS2022 @RWCSmtg Dr. Susan Shenoi https://t.co/qUts9X8gwJ
Dr. John Cush @RheumNow( View Tweet )
Feb 19, 2022
Dr Artie Kavanaugh presents comparison of targeted therapies in different inflammatory disorders. #RWCS2022 @RWCSmtg https://t.co/cX00RUOgAq
Dr. John Cush @RheumNow( View Tweet )
Feb 18, 2022
New 2021 JIA guidelines w 55 recommendations, 36 conditional and 19 strong. #RWCS2022 @RWCSmtg Dr Susan Shenoi https://t.co/CMETQeOdch
Dr. John Cush @RheumNow( View Tweet )
Feb 17, 2022
coronavirus,COVID,MISC,mask

ACR Updates Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With COVID

Feb 09, 2022

A Task Force from the ACR has provided an updated (version 3) guidance for the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C), a COVID related condition characterized by fever, inflammation, and multiorgan dysfunction. The current guidance also applies to

Read Article
UTSW Rheum Grand Rounds New and concerning: sJIA associated lung disease - rare and associated w/ pulmonary HTN, alveolar proteinosis, high mortality. Unique features: clubbing, eosinophilia, TCZ anaphylaxis, Trisomy 21. Most were Rx w/ IL-1 > IL-6 inhibition @UTSWRheum https://t.co/aJaPurDSmJ
Dr. John Cush @RheumNow( View Tweet )
Jan 20, 2022
UTSW Rheum Grand Rounds Treating STill's (sJIA) - early early use of anakinra yields best results (in remission and off steroids) - 91% if Anakinra started within the first 3 mos @UTSWRheum https://t.co/neozpYhJtM
Dr. John Cush @RheumNow( View Tweet )
Jan 20, 2022
UTSW Rheum Grand Rounds MAS occurs in 2-8% of Systemic JIA pts and has a high mortality (<40%); It is more frequent w/ onset in Years 1-4. Treatment - steroids, anakinra, etoposide or CsA & Rx infxn if present. Oh...dont stop the anakinra! @UTSWRheum https://t.co/09uQm3LURC
Dr. John Cush @RheumNow( View Tweet )
Jan 20, 2022
UTSW Rheum Grand Rounds IL-18 levels are elevated in systemic JIA, MAS and AOSD @UTSWRheum https://t.co/pIYKf4pods
Dr. John Cush @RheumNow( View Tweet )
Jan 20, 2022
Dr. Peter Nigrovic asserts the division between pediatric and adult arthritis is senseless and has no firm biologic basis. Instead we should consider pts as sero- positive or negative, Systemci or Spondyloarthropathy. @UTSWRheum https://t.co/zx5oQmUQ6Y
Dr. John Cush @RheumNow( View Tweet )
Jan 20, 2022
UTSW Rheum Grand Rounds with Dr. Peter Nigrovic on systemic JIA in children and adults; yes, its the same disease with the same features. @UTSWRheum https://t.co/C7eBFjnDIi
Dr. John Cush @RheumNow( View Tweet )
Jan 20, 2022
RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jan 14, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.




  1. Study 126 rheumatic disease (RMD) patients showed that

Read Article
×